[
  {
    "ts": null,
    "headline": "Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus?",
    "summary": "In recent days, Eli Lilly announced new long-term clinical data for Omvoh showing sustained efficacy and safety in ulcerative colitis, while also strengthening its leadership in obesity and diabetes treatments with continued strong performance from Mounjaro and Zepbound. The company's active recruitment of high-profile former FDA leaders and progress in expanding digital health initiatives further highlight its ongoing focus on innovation and regulatory expertise. We'll examine how Omvoh's...",
    "url": "https://finnhub.io/api/news?id=3e3f11d939a0b4c1d1f5184e5f270a2cbb56cae8633f838e9997b580d6b9c1d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760278267,
      "headline": "Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus?",
      "id": 137063472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In recent days, Eli Lilly announced new long-term clinical data for Omvoh showing sustained efficacy and safety in ulcerative colitis, while also strengthening its leadership in obesity and diabetes treatments with continued strong performance from Mounjaro and Zepbound. The company's active recruitment of high-profile former FDA leaders and progress in expanding digital health initiatives further highlight its ongoing focus on innovation and regulatory expertise. We'll examine how Omvoh's...",
      "url": "https://finnhub.io/api/news?id=3e3f11d939a0b4c1d1f5184e5f270a2cbb56cae8633f838e9997b580d6b9c1d7"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Novo Nordisk Right Now?",
    "summary": "The fallen pharma giant could make a big comeback in 2026.",
    "url": "https://finnhub.io/api/news?id=e53a86dd95c8c526afc9d425bf03f51e60ce4be11437a5504781db9b256e15ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760276580,
      "headline": "Should You Buy Novo Nordisk Right Now?",
      "id": 137063473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The fallen pharma giant could make a big comeback in 2026.",
      "url": "https://finnhub.io/api/news?id=e53a86dd95c8c526afc9d425bf03f51e60ce4be11437a5504781db9b256e15ab"
    }
  },
  {
    "ts": null,
    "headline": "QGRW: Leading Growth ETF With A Caveat",
    "summary": "Discover QGRW ETF: blending growth & quality in large-cap stocks, outperforming peers but with higher volatility.",
    "url": "https://finnhub.io/api/news?id=f6c6053438f4fd25de8b169e55a88b33958008e521c03c2e5745794154249c57",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760258153,
      "headline": "QGRW: Leading Growth ETF With A Caveat",
      "id": 137057859,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1394881057/image_1394881057.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover QGRW ETF: blending growth & quality in large-cap stocks, outperforming peers but with higher volatility.",
      "url": "https://finnhub.io/api/news?id=f6c6053438f4fd25de8b169e55a88b33958008e521c03c2e5745794154249c57"
    }
  }
]